“Why do neurons die?” Those four words, asked in a dorm room at Brown University in 2013, launched Amylyx into existence and began our journey to develop a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases.
After methodically poring over an endless supply of scientific literature, founders Josh Cohen and Justin Klee decided the best way to prevent degradation in these diseases was to focus on preserving neurons. What started as a question became a clinical reality: Amylyx has since advanced its oral drug candidate, AMX0035, into clinical trials in ALS (CENTAUR; trial completed) and Alzheimer’s disease (PEGASUS; fully enrolled).
Every day at Amylyx we’re working to turn neurodegenerative diseases from rapidly progressing conditions into ones that can be managed medically. Together we can rewrite what’s possible.